Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 30

References for PMC Articles for PubMed (Select 21549714)

1.

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development.

Graham BS.

Immunol Rev. 2011 Jan;239(1):149-66. doi: 10.1111/j.1600-065X.2010.00972.x. Review.

2.

Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design.

Correia BE, Ban YE, Friend DJ, Ellingson K, Xu H, Boni E, Bradley-Hewitt T, Bruhn-Johannsen JF, Stamatatos L, Strong RK, Schief WR.

J Mol Biol. 2011 Jan 7;405(1):284-97. doi: 10.1016/j.jmb.2010.09.061. Epub 2010 Oct 20.

PMID:
20969873
3.

Elicitation of structure-specific antibodies by epitope scaffolds.

Ofek G, Guenaga FJ, Schief WR, Skinner J, Baker D, Wyatt R, Kwong PD.

Proc Natl Acad Sci U S A. 2010 Oct 19;107(42):17880-7. doi: 10.1073/pnas.1004728107. Epub 2010 Sep 27.

4.

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope.

Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, Kraft Z, Carrico C, Boni E, Sather DN, Zenobia C, Burke KY, Bradley-Hewitt T, Bruhn-Johannsen JF, Kalyuzhniy O, Baker D, Strong RK, Stamatatos L, Schief WR.

Structure. 2010 Sep 8;18(9):1116-26. doi: 10.1016/j.str.2010.06.010.

5.

A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.

Chen M, Chang JS, Nason M, Rangel D, Gall JG, Graham BS, Ledgerwood JE.

J Immunol Methods. 2010 Oct 31;362(1-2):180-4. doi: 10.1016/j.jim.2010.08.005. Epub 2010 Aug 19.

6.

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis.

Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simões EA, Rudan I, Weber MW, Campbell H.

Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1. Review.

7.

Structural basis of respiratory syncytial virus neutralization by motavizumab.

McLellan JS, Chen M, Kim A, Yang Y, Graham BS, Kwong PD.

Nat Struct Mol Biol. 2010 Feb;17(2):248-50. doi: 10.1038/nsmb.1723. Epub 2010 Jan 24.

8.

Phaser crystallographic software.

McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ.

J Appl Crystallogr. 2007 Aug 1;40(Pt 4):658-674. Epub 2007 Jul 13.

9.

The burden of respiratory syncytial virus infection in young children.

Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P.

N Engl J Med. 2009 Feb 5;360(6):588-98. doi: 10.1056/NEJMoa0804877.

10.

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease.

Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP.

Nat Med. 2009 Jan;15(1):34-41. doi: 10.1038/nm.1894. Epub 2008 Dec 14.

11.

MolProbity: all-atom contacts and structure validation for proteins and nucleic acids.

Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB 3rd, Snoeyink J, Richardson JS, Richardson DC.

Nucleic Acids Res. 2007 Jul;35(Web Server issue):W375-83. Epub 2007 Apr 22.

12.

Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract.

Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA.

J Mol Biol. 2007 May 4;368(3):652-65. Epub 2007 Feb 20.

PMID:
17362988
13.

A time- and cost-efficient system for high-level protein production in mammalian cells.

Aricescu AR, Lu W, Jones EY.

Acta Crystallogr D Biol Crystallogr. 2006 Oct;62(Pt 10):1243-50. Epub 2006 Sep 19.

PMID:
17001101
14.

Reassembly of active caspase-3 is facilitated by the propeptide.

Feeney B, Clark AC.

J Biol Chem. 2005 Dec 2;280(48):39772-85. Epub 2005 Oct 3.

15.

Coot: model-building tools for molecular graphics.

Emsley P, Cowtan K.

Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32. Epub 2004 Nov 26.

PMID:
15572765
16.

Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants.

Zhao X, Chen FP, Megaw AG, Sullender WM.

J Infect Dis. 2004 Dec 1;190(11):1941-6. Epub 2004 Oct 27.

17.

Structural basis for recognition by an in vitro evolved affibody.

Högbom M, Eklund M, Nygren PA, Nordlund P.

Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3191-6. Epub 2003 Feb 25.

18.

PHENIX: building new software for automated crystallographic structure determination.

Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC.

Acta Crystallogr D Biol Crystallogr. 2002 Nov;58(Pt 11):1948-54. Epub 2002 Oct 21.

PMID:
12393927
19.

Native protein sequences are close to optimal for their structures.

Kuhlman B, Baker D.

Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10383-8. Erratum in: Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13460.

20.

The Protein Data Bank.

Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE.

Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk